Beachhead Market: LVAD patients
25% of LVAD patients develop post-operative right heart failure (RHF) .
Elevated CVP and congestion are primary contributors to RHF.
Hemodynamic monitoring and CVP optimization are essential for managing and preventing RHF.
The VenoDynamics System can peri- and post-operatively monitor and control CVP to reduce the risk of RHF.
Heart failure begins when the heart does not efficiently pump blood to the body.
Blood flow (cardiac output) decreases and the volume load on the heart (preload) increases.
The kidneys perceive the body to be dehydrated due to reduced cardiac output
The kidneys respond by holding on to blood volume leading to congestion
Expansion Market: Congestive Heart Failure
Current Solution
The gold standard of care is pharmaceutical intervention - primarily loop diuretics.
The goal of this medication is to offload fluid through increased urine output - decreasing congestion and alleviating pressures on the heart and lungs.
More than 20% of patients will develop diuretic resistance.
Finding the correct dosage takes time that some patients do not have - especially end-stage heart failure patients receiving a Left Ventricular Assist Device (LVAD) or transplant.
Our solution is to mechanically reduce congestion and promote diuresis with a simple, minimally invasive procedure.
By reducing the pressure around the renal veins and lowering cardiac preload, the kidneys resume their natural function and begin offloading fluid volume.
Partially occluding the vena cava with a standard large-vessel occlusion balloon creates a pressure gradient that lowers central venous and renal pressures.
Our closed-loop monitoring system monitors these pressures and cardiac output to optimize patient hemodynamics and promote diuresis.
